B. J. Hoogwerf
Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes
Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting
Diabetes, Obesity & Metabolism.
Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial
Annals of Internal Medicine.
Map of science